Intense Radiation + Chemotherapy for Lung Cancer

Recruiting at 6 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Proton Collaborative Group

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

Research Team

Brad Hoppe, MD

Principal Investigator

Proton Collaborative Group

Eligibility Criteria

This trial is for adults with stage II-III non-small cell lung cancer who can't have surgery. They should be in good physical condition, not pregnant, willing to use contraception, and haven't lost a lot of weight recently. No prior chest radiation or evidence of cancer spread far from the lung is allowed.

Inclusion Criteria

Your lab test results must be from within the 4 weeks before you join the study.

Your white blood cell count must be higher than 1,800 cells/mm3.

You have at least 100,000 platelets per cubic millimeter of blood.

Exclusion Criteria

I have had radiation therapy to my chest area before.

I have lost more than 10% of my weight without trying in the last month.

I am not pregnant or breastfeeding and willing to use contraception during and for 12 months after the study.

Treatment Details

Interventions

• Concurrent Chemotherapy (Chemotherapy)
• Hypofractionated Proton Therapy (Proton Beam Therapy)

Trial Overview The study tests if giving higher daily doses of proton radiation therapy over fewer days (hypofractionation) combined with standard chemotherapy works better for treating non-small cell lung cancer than current methods.

Participant Groups

Group I: Proton Radiotherapy with Chemotherapy Experimental Treatment 1 Intervention

Concurrent Chemotherapy is already approved in Canada for the following indications:

Approved in Canada as Concurrent Chemotherapy for:

• Locally advanced cervical cancer

Who Is Running the Clinical Trial?

Proton Collaborative Group

Lead Sponsor

Trials

10

Recruited

41,100+